Related references
Note: Only part of the references are listed.Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Surgical Outcome Results From SWOG S1505 A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma
Syed A. Ahmad et al.
ANNALS OF SURGERY (2020)
Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer
Jin-Zhi Xu et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Shades of Gray in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria Debated indications for surgery in pancreatic cancer
P. Lombardi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Pancreatic surgery: we need clear definitions
Andre Mihaljevic et al.
LANGENBECKS ARCHIVES OF SURGERY (2019)
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
Shuji Isaji et al.
PANCREATOLOGY (2018)
Neoadjuvant and adjuvant chemotherapy in pancreatic cancer
Ulla Klaiber et al.
LANGENBECKS ARCHIVES OF SURGERY (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?
Amine Antonios et al.
FUTURE ONCOLOGY (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients
Mashaal Dhir et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2017)
Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association
Mahmoud M. Al-Hawary et al.
GASTROENTEROLOGY (2014)
Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic Therapy
Davendra P. S. Sohal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association
Mahmoud M. Al-Hawary et al.
RADIOLOGY (2014)
Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design
Matthew H. G. Katz et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
Share Paper
